Cytek Biosciences, Inc. provided revenue guidance for the year 2023. For the year, the company expects revenue for 2023 to be near the high end of the company?s most recent revenue guidance range of $188 million to $192 million, provided on November 9, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +2.31% | -2.70% | -36.84% |
Mar. 20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
Mar. 19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.84% | 756M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023